NRx Pharmaceuticals (Nasdaq: NRXP) has announced the appointment of Glenn Tyson as the company’s first Chief Commercial Officer as it anticipates approval of an Abbreviated New Drug Application (ANDA) for preservative-free ketamine and prepares for near-term submission of a New Drug Application to expand ketamine labeling to encompass depression and suicidality.
Tyson brings both clinical experience treating patients with serious mental health disorders and 25 years of successful industry commercial experience in developing and selling psychiatric medications. He began his career as a counselor in multiple settings working with children and adults with psychiatric conditions and addiction before transitioning to the pharmaceutical industry. Over his 25-year tenure in industry, he has gained expertise in all aspects of commercialization and sales.
At GSK, Tyson served in increasingly senior roles over 14 years. He then joined Indivior as Vice President of Strategy and New Product Development before becoming Senior Vice President of Sales and Marketing and subsequently President of Behavioral Health. At Indivior, he led the successful launch of SUBLOCADE, a once-monthly injectable for treating opioid addiction, delivering 17 consecutive quarters of double-digit growth during his tenure.
Most recently, Tyson has focused on the emerging sector of companies developing neuroplastic therapies for psychiatric conditions, including leadership-level work with Transcend Therapeutics, which recently announced a $700 million deal with Otsuka.
As Chief Commercial Officer, Tyson will be responsible for building world-class market-access, distribution, sales, and marketing functions to support commercialization of NRx’s pipeline. In addition to the pending ANDA for preservative-free ketamine, NRx is preparing a New Drug Application under Fast Track Designation to expand the use of intravenous ketamine (NRX-100) to treat patients with severe depression who may have suicidal ideation. The company is also developing D-cycloserine (NRX-101), previously awarded Breakthrough Therapy Designation, as a neuroplastogen to enhance transcranial magnetic stimulation efficacy in treating depression and suicidality.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.biospace.com/press-releases/nrx-pharmaceuticals-nasdaq-nrxp-announces-appointment-of-glenn-tyson-as-the-companys-first-chief-commercial-officer